Zai Lab Ltd (NAS:ZLAB)
$ 17.92 -1.14 (-5.98%) Market Cap: 1.79 Bil Enterprise Value: 1.34 Bil PE Ratio: 0 PB Ratio: 2.43 GF Score: 67/100

Zai Lab Ltd at Citi BioPharma Conference (Virtual) Transcript

Sep 10, 2020 / 12:55PM GMT
Release Date Price: $74 (-5.73%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Okay, great. So welcome, everyone, to the third day of the Citi Biopharma Conference. I'm Yigal Nochomovitz, one of the Biotech analysts. (Operator Instructions). So it's my great pleasure to have with me this morning, Samantha Du, the CEO of Zai Lab, one of the companies I cover.

Questions & Answers

Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

And maybe as a starting point, Samantha, just to get everyone oriented, if you could give us a 3- or 4-minute overview of Zai Lab, just highlighting some of the key assets in the pipeline and where you stand with your commercial efforts for ZEJULA and Optune.

Ying Du
Zai Lab Limited - Founder, Chairman & CEO

Yes. Good morning, Yigal, and thank you for your opening remarks. Since our inception in 2014, we have executed our two-pronged strategy through both in-licensing of potentially best-in-class and first-in-class assets and investing in internal R&D efforts. Today,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot